Stockscreener 앱 받기
17.79
5.97%
-1.13
시간 외 거래:
17.74
-0.05
-0.28%
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Capricor stock on watch after key EU designations (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency - The Manila Times
(CAPR) Proactive Strategies - Stock Traders Daily
Capricor Therapeutics shares rated Buy by Jones Trading, boosted by DMD-CM therapy - Investing.com Canada
HC Wainwright Brokers Increase Earnings Estimates for CAPR - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October - MarketBeat
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Quarterly 10-Q Report - Quartzy
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Earnings call: Capricor outlines deramiocel's path to market for DMD treatment - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher on Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
Decoding 12 Analyst Evaluations For Capricor Therapeutics - Benzinga
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates - MSN
Capricor Therapeutics Advances with Strategic Expansions - TipRanks
Capricor: Q3 Earnings Snapshot - San Antonio Express-News
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
CAPRCapricor Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Capricor Therapeutics to Present Exosome Platform Updates - GlobeNewswire
Capricor's StealthX Platform Shows Promise in DMD Treatment, Shares New Data | CAPR Stock News - StockTitan
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $24.67 Average Price Target from Analysts - Defense World
Objective long/short (CAPR) Report - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 10.6%What's Next? - MarketBeat
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Capricor Therapeutics (CAPR) Scheduled to Post Earnings on Wednesday - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline - Yahoo Finance
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13 - The Manila Times
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 17.9% in October - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 3.3%Time to Sell? - MarketBeat
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Here's What Could Help Capricor (CAPR) Maintain Its Recent Price Strength - Yahoo Finance
Capricor Therapeutics Options Trading: A Deep Dive into Market Sentiment - Benzinga
Piper Sandler Initiates Coverage of Capricor Therapeutics (CAPR) with Overweight Recommendation - MSN
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been enviable, earning 685% in 5 years - Simply Wall St
Capricor Therapeutics initiated at Overweight by Piper Sandler - MSN
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 4.3%Here's Why - MarketBeat
Piper Sandler Begins Coverage on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics stock outlook driven by DMD drug potential, says Piper Sandler - Investing.com Canada
Cash raises for Inventiva, Akeso, Capricor - BioCentury
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times
Capricor Therapeutics Announces Closing of Underwritten - GlobeNewswire
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - StockTitan
Form 424B5 CAPRICOR THERAPEUTICS, - StreetInsider.com
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap DownHere's What Happened - MarketBeat
0.93%
3.55%
자본화:
|
볼륨(24시간):